The Latest Articles from Streetwise Reports


Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data

  ()
Shares of Aurinia Pharmaceuticals traded much higher after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. read more >
News Update

Company Vies for New Brunswick Cannabis Contract

News Update
  ()
The opportunity is one of the largest in retail cannabis in Canada. read more >

Immuno-Oncology Firm Expands Agreement with AbbVie

Research Report
  ()
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. read more >
News Update

Cannabis Producer Signs Supply Contract with Province of Alberta

News Update
  ()
To start, the company will introduce its premium brand of dried flower there. read more >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. read more >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

  ()
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. read more >

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

  ()
Axsome Therapeutics shares traded higher after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. read more >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

  ()
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. read more >

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

  ()
Shares of ChemoCentryx Inc. opened greater than 330% higher after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. read more >
News Update

Healthcare Tech Firm Expands Client Base in Texas

News Update
  ()
The company signs six new contracts for its telemedicine-based platform. read more >
News Update

Regenerative Medicine Firm Advances Multifaceted Pipeline

News Update
  ()
The company continues advancing its cell therapies and medical device. read more >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

Research Report
  ()
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. read more >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

  ()
Shares of Intercept Pharmaceuticals rose after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. read more >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

  ()
EyeGate Pharmaceuticals shares opened nearly 85% higher after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. read more >

Cannabis Firm's Stock Poised for 'Substantial Gains'

Contributed Opinion
  ()
Technical analyst Clive Maund charts how news from this company affects its investment thesis. read more >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results

  ()
Shares of Hepion Pharmaceuticals opened higher after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. read more >

ICAN Leverages Leading California Brand with Expansion into Nevada, Introduces State-of-the-Art Pre-Roll Machine, for Aggressive Near-Term Growth

Contributed Opinion
  ()
A recent acquisition is helping this company to expand its brand. read more >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

  ()
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. read more >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

  ()
Shares of Myovant Sciences opened 120% higher after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. read more >
News Update

Firm to Acquire CBD Products Designer

News Update
  ()
The deal encompasses all of the company's brands, formulations and processes. read more >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

  ()
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. read more >

Medical Small Cap Moving Forward with Cutting-Edge Technological Innovations

  ()
Premier Health is methodically building an innovative telemedicine platform in Canada, is purchasing a venerable telemedicine firm, and sees 2020 as the year of execution. read more >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

  ()
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. read more >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

  ()
Plus Therapeutics shares traded higher after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. read more >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

  ()
Shares of Exicure Inc. opened 30% higher after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. read more >
Showing Results: 1 to 25 of 187 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts